GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2011

Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing

Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing

Technology developed by Biodesign Institute and Columbia University will be used alongside DNA transistor platform developed by IBM.[Andrzej -]

  • Roche negotiated a license to nanopore-based DNA base sensing and reading technologies from the Biodesign Institute at Arizona State University and the Columbia University Nanoscience Center. The firm claims that these new technologies could help take the cost of sequencing a whole human genome down to well under $1,000.

    The technologies will be used by Roche’s sequencing center and collaborators 454 Life Sciences and IBM to develop and commercialize a single-molecule nanopore DNA sequencer. The deal was brokered by Arizona State University’s technology transfer arm, Arizona Technology Enterprises, and includes sponsored research funding to help the academic researchers progress development of the technology toward commercialization.

    “We believe that the DNA reading technologies from the Biodesign Institute are the most advanced available and will play an important role in our nanopore sequencing system,” says Thomas Schinecker, president of Roche’s 454 Life Sciences. “This will complement the DNA Transistor technology from our previously announced collaboration with IBM very well to form the core of a superior platform for extremely fast, very low-cost genome sequencing.”

    IBM’s DNA Transistor technology is designed to control and slow the movement of DNA as it passes through the nanopore in a silicone strip. The DNA reading technology licensed from the Biodesign Institute and Columbia University will be used to decode the bases as the molecule passes through. Both technologies exploit semiconductor-based nanopores, which Roche says have advantages over protein-based nanoproes in terms of control, robustness, scalability, and production. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »